全文获取类型
收费全文 | 1777篇 |
免费 | 66篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 6篇 |
妇产科学 | 16篇 |
基础医学 | 438篇 |
口腔科学 | 23篇 |
临床医学 | 125篇 |
内科学 | 261篇 |
皮肤病学 | 16篇 |
神经病学 | 138篇 |
特种医学 | 57篇 |
外科学 | 87篇 |
综合类 | 162篇 |
预防医学 | 99篇 |
眼科学 | 5篇 |
药学 | 335篇 |
中国医学 | 46篇 |
肿瘤学 | 69篇 |
出版年
2023年 | 14篇 |
2022年 | 25篇 |
2021年 | 38篇 |
2020年 | 31篇 |
2019年 | 21篇 |
2018年 | 40篇 |
2017年 | 28篇 |
2016年 | 49篇 |
2015年 | 59篇 |
2014年 | 107篇 |
2013年 | 128篇 |
2012年 | 102篇 |
2011年 | 114篇 |
2010年 | 72篇 |
2009年 | 100篇 |
2008年 | 97篇 |
2007年 | 95篇 |
2006年 | 77篇 |
2005年 | 95篇 |
2004年 | 74篇 |
2003年 | 57篇 |
2002年 | 33篇 |
2001年 | 36篇 |
2000年 | 21篇 |
1999年 | 26篇 |
1998年 | 16篇 |
1997年 | 48篇 |
1996年 | 24篇 |
1995年 | 35篇 |
1994年 | 37篇 |
1993年 | 35篇 |
1992年 | 17篇 |
1991年 | 12篇 |
1990年 | 8篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 9篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1969年 | 2篇 |
1968年 | 3篇 |
排序方式: 共有1890条查询结果,搜索用时 140 毫秒
1.
Paulina Marta Gajda Niels Bjerre Holm Lars Jakobsen Hoej Brian Schou Rasmussen Petur Weihe Dalsgaard Lotte Ask Reitzel Kristian Linnet 《Drug testing and analysis》2019,11(2):350-354
A number of unknown pharmaceutical preparations seized by Danish customs authorities were submitted for liquid chromatography–high resolution mass spectrometry (LC–HRMS) analysis. Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP‐2 (Pralmorelin), GHRP‐6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1–29), which can be used as performance‐enhancing substances in sports. In all cases, the detected modification involved the addition of an extra glycine amino acid at the N‐terminus, and analytical methods targeting growth hormone secretagogues should hence be updated accordingly. 相似文献
2.
3.
《Vaccine》2021,39(30):4099-4107
The fungal genus Candida includes common commensals of the human mucosal membranes, and the most prevalently isolated species, C. albicans, poses a threat of candidemia and disseminated infection associated with an unacceptably high mortality rate and an immense $4 billion burden (US) yearly. Nevertheless, the demand for a vaccine remains wholly unfulfilled and increasingly pressing. We developed a double-peptide construct that is feasible for use in humans with the intention of preventing morbid infection by targeting epitopes derived from fructose bisphosphate aldolase (Fba) and methionine synthase (Met6) which are expressed on the C. albicans cell surface. To test the applicability of the design, we vaccinated mice via the intramuscular (IM) route with the conjugate denoted Fba-Met6 MP12 and showed that the vaccine enhanced survival against a lethal challenge. Because overall endpoint IgG1 and IgG2a antibody titers were robust and these mouse subclasses are associated with protective functionality, we investigated the potential of Fba and Met6 specific antibodies to facilitate the well-defined anti-Candida response by complement, which opsonizes fungi for degradation by primary effectors. Notably, reductions in the fungal burdens and enhanced survival were both abrogated in MP12-vaccinated mice that were pre-challenge dosed with cobra venom factor (CVF), a complement depleting factor. Altogether, we demonstrated that complement is relevant to MP12-based protection against disseminated C. albicans, delineating that a novel, multivalent targeted vaccine against proteins on the surface of C. albicans can enhance the natural response to infection. 相似文献
4.
《Joint, bone, spine : revue du rhumatisme》2022,89(6):105407
ObjectiveTo investigate the potential role of US in the detection of ILD in a cohort of patients with RA.MethodsPatients with diagnosis of RA were consecutively enrolled. All patients underwent pulmonary examination, laboratory data, DLCO measure, chest HRCT and radiographs, and US examination. A healthy group was included as control group. US was performed according the 14-intercostal space scanning protocol using the following semiquantitative scale [0 = normal (≤ 5 B-lines); 1 = slight (≥ 6 and ≤ 15 B-lines); 2 = moderate, (≤ 16 and ≥ 30 B-lines); 3 = severe (≥ 30 B-lines)].ResultsA total of 74 RA patients and 74 healthy controls were included. Thirty of 74 patients (40.5%) showed US signs of ILD with respect to the healthy controls (3 subjects, 4.1%) (P < 0.001); whereas HRCT showed ILD in 27 (36.4%) of 74 patients. Among the 30 patients that showed US findings of ILD, 17 (56.6%) were asymptomatic from respiratory view-point. The sensitivity and specificity of US were 92% and 89% respectively. A positive correlation between US and HRCT findings were found (P < 0.001) whereas no correlation was found with chest radiographs and DLCO findings. Positive association between US findings and DAS28-ESR, anti-CCP and RF (P < 0.01 for each respectively) was found. Feasibility, represented by the mean time spent to perform the pulmonary US assessment was 7.8 minutes (± SD 1.2, range 6 to 10 minutes).ConclusionsOur results support the potential of US in detect accurately ILD in patients with RA and provide a rationale to consider it as a friendly screening tool to be implemented in early phases of the disease. 相似文献
5.
《Drug discovery today》2022,27(5):1367-1380
The tremendous advances in genomics, recombinant DNA technology, bioengineering and nanotechnology, in conjunction with the development of high-end computations, have been instrumental in the process of rational design of peptide-based vaccines. The use of peptide vaccines was limited owing to their inherent instability when systemically administered; however, advanced formulation techniques have been developed for their systemic delivery, thereby overcoming their degradation, clearance, cellular uptake and off-target effects. With the rise of sophisticated immunological predictors and experimental techniques, several methodological advances have occurred in this field. This review examines contemporary methods to identify and optimize epitopes, engineer their immunogenic properties and develop their safe and efficient delivery into the host. 相似文献
6.
Nicole Segaran Catherine Devine Mindy Wang Dhakshinamoorthy Ganeshan 《World journal of clinical oncology》2021,12(10):897-911
Pancreatic neuroendocrine neoplasms (panNEN) are a heterogeneous group of tumors with differing pathological, genetic, and clinical features. Based on clinical findings, they may be categorized into functioning and nonfunctioning tumors. Adoption of the 2017 World Health Organization classification system, particularly its differentiation between grade 3, well-differentiated pancreatic neuroendocrine tumors (panNET) and grade 3, poorly-differentiated pancreatic neuroendocrine carcinomas (panNEC) has emphasized the role imaging plays in characterizing these lesions. Endoscopic ultrasound can help obtain biopsy specimen and assess tumor margins and local spread. Enhancement patterns on computed tomography (CT) and magnetic resonance imaging (MRI) may be used to classify panNEN. Contrast enhanced MRI and diffusion-weighted imaging have been reported to be useful for characterization of panNEN and quantifying metastatic burden. Current and emerging radiotracers have broadened the utility of func tional imaging in evaluating panNEN. Fluorine-18 fluorodeoxyglucose positron emission tomography (PET)/CT and somatostatin receptor imaging such as Gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid–octreotate PET/CT may be useful for improved identification of panNEN in comparison to anatomic modalities. These new techniques can also play a direct role in opti mizing the selection of treatment for individuals and predicting tumor response based on somatostatin receptor expression. In addition, emerging methods of radiomics such as texture analysis may be a potential tool for staging and outcome prediction in panNEN, however further investigation is required before clinical implementation. 相似文献
7.
《Pancreatology》2016,16(5):829-838
Background/objectivesPancreatic ductal adenocarcinoma (PDAC) is frequently heralded by an impairment of glucose homeostasis. Dipeptidyl peptidase-IV (DPP-IV) and fibroblast activation protein alpha (FAP) are aminopeptidases that regulate several bioactive peptides involved in glucoregulation, and are frequently dysregulated in cancer. The present study analyzes blood plasma levels and the quantity and localization of DPP-IV and FAP in PDAC tissues.MethodsDPP-IV and FAP concentration and enzymatic activity were evaluated in the plasma from 93 PDAC, 39 type 2 diabetes mellitus (T2DM) and 29 control subjects, and in matched paired non-tumorous and tumor tissues from 48 PDAC patients. The localization of DPP-IV and FAP was determined using immunohistochemistry and catalytic histochemistry.ResultsThe enzymatic activity and concentration of DPP-IV was higher in PDAC tumor tissues compared to non-tumorous pancreas. DPP-IV was expressed in cancer cells and in the fibrotic stroma by activated (myo)fibroblasts including DPP-IV+FAP+ cells. FAP was expressed in stromal cells and in some cancer cells and its expression was increased in the tumors. Plasmatic DPP-IV enzymatic activity, and in particular the ratio between DPP-IV enzymatic activity and concentration in PDAC with recent onset DM was higher compared to T2DM. In contrast, the plasmatic FAP enzymatic activity was lower in PDAC compared to T2DM and controls and rose after tumor removal.ConclusionsDPP-IV-like enzymatic activity is upregulated in PDAC tissues. PDAC patients with recent onset diabetes or prediabetes have increased plasmatic DPP-IV enzymatic activity. These changes may contribute to the frequently observed association of PDAC and recent onset impairment of glucoregulation. 相似文献
8.
9.
Objective
Antigen I/II of mutans streptococcus (MS) is a surface protein, which binds to salivary receptors. The objective of this study was to study the effect of a peptide corresponding to residues 1025-1044 of antigen I/II and a dentifrice containing peptide on the adherence of MS.Methods
The peptide was synthesized and included into dentifrice. Anti-adherence experiments of the peptide and a dentifrice containing it were processed in vitro and in vivo.Results
The results showed that the adherence of MS to hydroxyapatite was inhibited by synthetic antigen I/II peptide and also by a dentifrice containing the peptide in vitro. The numbers of MS in plaque from subjects treated with dentifrices containing the peptide for 1 month was significantly reduced compared to baseline (log 3.11 ± 0.80 vs log 4.09 ± 0.90, P < 0.01), whereas the control group showed no reduction.Conclusion
The adherence of MS to hydroxyapatite was inhibited by both a synthetic peptide and a dentifrice containing the peptide. The peptide dentifrice produced a significant reduction of MS in dental plaque in vivo. 相似文献10.
Cabras T Castagnola M Inzitari R Ekström J Isola M Riva A Messana I 《Archives of oral biology》2008,53(11):1077-1083